{{Drugbox
| IUPAC_name = 
| image = 
<!-- Clinical data -->
| tradename = Fragmin 
| Drugs.com = {{drugs.com|international|dalteparin-sodium}}
| pregnancy_AU = C 
| pregnancy_US = B
| pregnancy_category = 
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
| legal_CA = <!--             / Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL         / P       / POM / CD / Class A, B, C -->
| legal_US = Rx-only
| legal_status = 
| routes_of_administration = subcutaneous
<!-- Pharmacokinetic data -->
| bioavailability = 81-93%
| protein_bound = 
| metabolism = 
| elimination_half-life = 3-5 hours subcutaneous; 2.1-2.3 hours IV
| excretion = Renal
<!-- Identifiers -->
| CAS_number_Ref = {{cascite|correct|CAS}}
| CAS_number = 9041-08-1
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 12M44VTJ7B
| ATC_prefix = B01
| ATC_suffix = AB04
| PubChem = 
| DrugBank = DB06779
| KEGG = D03353
| ChemSpiderID = none
<!-- Chemical data -->
| chemical_formula = 
| molecular_weight = 
}}'''Dalteparin''' is a [[low molecular weight heparin]].  It is marketed as '''Fragmin''' by [[Pfizer|Pfizer Inc]]. Like other low molecular weight heparins, dalteparin is used for prophylaxis or treatment of [[deep vein thrombosis]] and [[pulmonary embolism]]. It is normally administered by self-injection.

The CLOT study, published in 2003, showed that in patients with malignancy and acute [[venous thromboembolism]], dalteparin was more effective than [[warfarin]] in reducing the risk of recurrent embolic events.<ref>{{cite journal | vauthors=Lee AY, Levine MN, Baker RI, Bowden C, Kakkar AK, Prins M, Rickles FR, Julian JA, Haley S, Kovacs MJ, Gent M | author5-link=Ajay Kakkar, Baron Kakkar| title=Low-molecular-weight heparin versus a Coumadin for the prevention of recurrent venous thromboembolism in patients with cancer | journal=N Engl J Med | year=2003 | pages=146–53 | volume=349 | issue=2 | pmid=12853587 | doi=10.1056/NEJMoa025313}}</ref> Dalteparin is not superior to [[unfractionated heparin]] in preventing blood clots.<ref>{{cite journal|author=The PROTECT Investigators for the Canadian Critical Care Trials Group and the Australian and New Zealand Intensive Care Society Clinical Trials Group|title=Dalteparin versus unfractionated heparin in critically ill patients|year=2011|doi=10.1056/NEJMoa1014475}}</ref>

Heparins are cleared by the kidneys, but studies have shown that dalteparin does not accumulate even if kidney function is reduced.<ref>{{cite journal | vauthors=Douketis J, Cook D, Meade M | title=Prophylaxis against deep vein thrombosis in critically ill patients with severe renal insufficiency with the low-molecular-weight heparin dalteparin | journal=Arch Intern Med | year=2008 | volume=168 | issue=16 | pmid=18779469 | pages=1805–1812 | doi=10.1001/archinte.168.16.1805|display-authors=etal}}</ref>

==References==
<references/>

{{Antithrombotics}}

[[Category:Heparins]]